Jamese Johnson
7 Papers
5 Citations
Jamese Johnson is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Financial toxicity and cancer-related distress among melanoma survivors.
TL;DR: Melanoma survivors are at risk for significant financial burden due to cancer care and out of pocket costs and the financial impact of melanoma and its relationship to other types of cancer is explored.
6
Symptom Burden, Palliative Care Needs, and Patient-Provider Communication Among Chronic Myeloid Leukemia Survivors
Alexandra K Zaleta,Melissa F. Miller,Jamese Johnson,Shauna McManus,Clare Karten,Michael J. Mauro,Joanne S. Buzaglo +6 more
TL;DR: Mauro et al. as mentioned in this paper examined CML patients' symptom burden, palliative care needs, and experiences with health care team (HCT) communication and found that patients with CML experience significant symptom burden and want more support with managing symptoms and side effects.
6
Chronic Lymphocytic Leukemia Patient Reported Outcomes and Quality of Life: Findings from the Cancer Experience Registry
Joanne S. Buzaglo,Melissa F. Miller,Alexandra K Zaleta,Jamese Johnson,Shauna McManus,Clare Karten,Christopher R. Flowers +6 more
TL;DR: Comparing how CLL patients describe their quality of life compared to other US population groups and the extent to which CLL affects daily life, finances, and professional and family relationships found that over one-fifth of CLL survivors are experiencing substantial levels of anxiety and fatigue, compared to the general U.S. population.
4
Cancer-related distress and cost of care concerns among gastric cancer patients.
Linda House,Melissa F. Miller,Alexandra K Zaleta,Jamese Johnson,Crystal S. Denlinger,Joanne S. Buzaglo +5 more
TL;DR: This study characterizes gastric cancer as a social determinant of death in men and women over the age of 40 with a history of smoking and alcohol abuse as a source of financial burden.
1
A phase II study of hypofractionated radiation therapy to augment immune response in patients with metastatic gastrointestinal malignancies progressing on immune therapy (ARM-GI).
Hewitt Chang,Luchia Andemicael,Moshiur Mekhail Anwar,John D. Gordan,Jamese Johnson,Bridget P. Keenan,Robin Kate Kelley,Andrew H. Ko,Katherine Van Loon,Alan P. Venook,Lawrence Fong,Melody J. Xu,Mary Feng +12 more
TL;DR: The ARM-GI study as mentioned in this paper studied the radiation-augmented immune response in patients with metastatic GI cancers progressing on immunotherapy, and the primary endpoint was overall response rate (ORR) per RECIST v1.1.